"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT03611946","Evaluation of the Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults",,"Completed","No Results Available","Zika Virus","Biological: rZIKV/D4Δ30-713|Biological: Placebo","Frequency of solicited local and general adverse events (AEs)|Frequency of unsolicited AEs|Frequency of medically-attended AEs and serious adverse events (SAEs)|Peak neutralizing antibody titer to ZIKV|Frequency of viremia|Determination of the neutralizing antibody titer to ZIKV","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 50 Years   (Adult)","Phase 1","28","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CIR 318","July 6, 2018","February 8, 2019","September 1, 2019","August 2, 2018",,"January 18, 2020","Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland, United States|University of Vermont Medical Center (UVMMC), Clinical Research Center, Burlington, Vermont, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT03611946/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03611946"
2,"NCT02937233","Zika Virus Purified Inactivated Vaccine (ZPIV) Accelerated Vaccination Schedule Study","Z001","Completed","No Results Available","Zika","Biological: Zika Virus Purified Inactivated Vaccine|Other: Placebo","Incidence, intensity, and relationship to vaccination of solicited local and systemic adverse events|Incidence, intensity, and relationship to vaccination of unsolicited local and systemic adverse events|Incidence, intensity, and relationship to vaccination of serious local and systemic adverse events|ZIKV microneutralization Log10 MN50 titers|Zika Env-specific Log10 endpoint ELISA titers|Zika Plaque reduction neutralization test titer|IFN-γ ELISPOT responses to prM, Env, Cap, and NS1 peptides","Kathryn Stephenson|Walter Reed Army Institute of Research (WRAIR)|National Institute of Allergy and Infectious Diseases (NIAID)|Beth Israel Deaconess Medical Center","All","18 Years to 50 Years   (Adult)","Phase 1","36","Other|U.S. Fed|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2016P000268","December 8, 2016","June 4, 2018","June 4, 2018","October 18, 2016",,"August 23, 2018","Center for Virology and Vaccine Research Clinical Trials Unit, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02937233"
3,"NCT04064905","Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults",,"Recruiting","No Results Available","Zika Virus","Biological: mRNA-1893|Other: Placebo","Frequency and grade of each solicited local and systemic reactogenicity adverse event (AE)|Frequency and grade of any unsolicited AEs|Frequency of any medically attended adverse event (MAAE), serious adverse event (SAE), and adverse event of special interest (AESI)|Geometric mean titer (GMT) of serum neutralizing antibodies (nAb) against zika virus (ZIKV) as measured by Plaque Reduction Neutralization Test (PRNT)|GMT of nAb in initially seronegative participants against ZIKV as measured by PRNT|GMT of nAb in initially seropositive participants against ZIKV as measured by PRNT|Percentage of participants who seroconverted|Proportion of initially seronegative participants with a seroresponse as measured by PRNT|Proportion of initially seropositive participants with a 2-fold or 4-fold increase in nAb titers as compared with baseline as measured by PRNT","ModernaTX, Inc.|Biomedical Advanced Research and Development Authority","All","18 Years to 49 Years   (Adult)","Phase 1","120","Industry|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","mRNA-1893-P101|BARDA HHS010020160029C","July 30, 2019","February 2021","July 2021","August 22, 2019",,"November 13, 2019","Meridan Clinical Research, Omaha, Nebraska, United States|Benchmark Research, Austin, Texas, United States|Benchmark Research, Fort Worth, Texas, United States|Ponce School of Medicine - CAIMED Center, Ponce, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT04064905"
4,"NCT03158233","Zika Case Definition and Surveillance Study",,"Completed","No Results Available","Zika Virus Disease",,"Number of participants with suspected ZVD and virologically confirmed Zika (VCZ) infection in the cohort|Summary of the signs and symptoms accompanying suspected ZVD and VCZ cases in the study participants","Sanofi Pasteur, a Sanofi Company|Sanofi","All","15 Years to 40 Years   (Child, Adult)",,"2400","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","VAG00001","April 29, 2017","December 19, 2018","December 19, 2018","May 18, 2017",,"May 24, 2019","Investigational Site, Floridablanca, Santander, Colombia|Investigational Site, Cali, Valle Del Cauca, Colombia|Investigational site, Tegucigalpa, Honduras|Investigational Site, Acapulco, Guerrero, Mexico|Investigational Site, Temixco, Morelos, Mexico|Investigational Site, Carolina, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT03158233"
5,"NCT04182685","Evaluation of Medical Conditions Associated With Zika Virus Infection in Managua, Nicaragua",,"Enrolling by invitation","No Results Available","Zika Virus",,"Prevalence of short-term self-reported neurological symptoms among ZIKV-exposed|Prevalence of short-term clinically-observed neurological symptoms among ZIKV-exposed|Incidence of long-term clinically-observed neurological sequelae|Incidence of long-term self-reported neurological sequelae|Neurocognitive function|Nonverbal Intelligence|Behavioral problems|Depression|Anxiety|Sleep problems","RTI International|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of North Carolina, Chapel Hill|Sustainable Sciences Institute (Managua, Nicaragua)|Ministry of Health Nicaragua","All","5 Years to 15 Years   (Child)",,"450","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","CNDR CIRE-16/07/19-099.Ver2|1R21HD095420-01A1","October 1, 2019","June 1, 2020","June 1, 2020","December 2, 2019",,"February 5, 2020","Health Center Socrates Flores Vivas, Managua, Nicaragua",,"https://ClinicalTrials.gov/show/NCT04182685"
6,"NCT04033068","Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP","MV-ZIKA-RSP","Recruiting","No Results Available","Zika Virus Infection","Biological: Two MV-ZIKA-RSP vaccinations (high dose)|Biological: Two MV-ZIKA-RSP vaccination (low dose)|Biological: One MV-ZIKA-RSP vaccination (high dose) and one placebo|Other: Two placebo injection","Frequency of Adverse Events|Functional anti-zika antibodies as measured by PRNT50 and ELISA|Induction of Zika specific T-cells assessed by FN-ɣIL-2 ELISPOT and FACS assays|Adverse Events and Serious Adverse Events","Themis Bioscience GmbH","All","18 Years to 55 Years   (Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MV-ZIKA-RSP|2019-000840-93","August 8, 2019","July 1, 2020","September 3, 2020","July 25, 2019",,"August 13, 2019","Institute of Specific Prophylaxis and Tropical Medicine, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT04033068"
7,"NCT03229421","Dermatologic Manifestations of Zika Virus","DMZV","Withdrawn","No Results Available","Zika Virus Symptoms and the Associated Exanthema","Other: Survey","Number of days with specific symptoms|Frequency measures of initial clinical presentations","Northwestern University|Pontificia Universidad Catolica Madre y Maestra","All","18 Years and older   (Adult, Older Adult)",,"0","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","STU00205325","July 6, 2017","December 31, 2018","December 31, 2018","July 25, 2017",,"February 4, 2019","Pontificia Universidad Catolica Madre y Maestra, Departamento de Medicina, Santo Domingo, Illinois, Dominican Republic",,"https://ClinicalTrials.gov/show/NCT03229421"
8,"NCT02996890","Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability",,"Completed","No Results Available","Zika Virus","Biological: MV-ZIKA|Other: Placebo","Immunogenicity: Functional anti-Zika antibodies as measured by PRNT","Themis Bioscience GmbH","All","18 Years to 55 Years   (Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MV-ZIKA-101|2016-004212-34","April 4, 2017","January 4, 2018","April 17, 2018","December 19, 2016",,"April 26, 2018","Medical University of Vienna, Center for Pathophysiology, Infectiology and Immunology, Vienna, Austria|Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT02996890"
9,"NCT03106714","Study on the Persistence of Zika Virus (ZIKV) in Body Fluids of Patients With ZIKV Infection in Brazil","ZikaBra","Active, not recruiting","No Results Available","Zika Virus","Diagnostic Test: RT-PCR","Persistence and duration of ZIKV","Oswaldo Cruz Foundation|World Health Organization|Ministry of Health, Brazil|Walter Reed Army Institute of Research (WRAIR)|Wellcome Trust|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Older Adult)",,"1300","Other|U.S. Fed|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","ERC.0002786|62518016.6.1001.0008","July 21, 2017","July 31, 2020","July 31, 2020","April 10, 2017",,"August 13, 2019","Tropical Medicine Foundation, Manaus, Amazonas, Brazil|Research Centre Aggeu Magalhães, Oswaldo Cruz Foundation, Recife, Pernambuco, Brazil|Evandro Chagas National Institute of Infectious Diseases - Oswaldo Cruz Foundation, Rio de Janeiro, Brazil",,"https://ClinicalTrials.gov/show/NCT03106714"
10,"NCT02979938","Understanding Excretion and Infectivity of Zika Virus in Semen During and After Infection",,"Completed","No Results Available","Zika Virus","Other: Semen analysis and semen PCR for Zika virus","Measurement of the presence (with RT-PCR) of ZIKV in semen|Measurement of the viral load (with ct values) of ZIKV in semen","Trinidad and Tobago IVF and Fertility Centre|Institute of Tropical Medicine, Belgium","Male","Child, Adult, Older Adult",,"25","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ZIKAFERTI","July 2016","May 2017","August 2017","December 2, 2016",,"May 7, 2018","Trinidad and Tobago IVF & Fertility Centre, Maraval, Trinidad and Tobago",,"https://ClinicalTrials.gov/show/NCT02979938"
11,"NCT02952833","ZIKA Vaccine in Naive Subjects",,"Completed","No Results Available","Zika Virus Infection","Drug: Saline|Biological: Zika Virus Purified Inactivated Vaccine (ZPIV)","Comparison between dosage groups of the duration of vaccine-related Grade 2 or greater local or systemic reactogenicity|Comparison between dosage groups of the duration overall and in each dosage group of vaccine-related Grade 3 local, systemic, or laboratory AE|Comparison between dosage groups of the frequency of vaccine-related Grade 2 or greater local or systemic reactogenicity|Comparison between dosage groups of the frequency of vaccine-related Grade 3 local, systemic, or laboratory AE|Comparison between dosage groups of the type of vaccine-related Grade 2 or greater local or systemic reactogenicity|Comparison between dosage groups of the type overall and each dosage group of vaccine-related Grade 3 local, systemic, or laboratory AE|Comparison of study withdrawals, and discontinuation of study vaccination due to any reason between dosage groups.|Duration overall and in each dosage group of serious adverse events (SAE) and adverse events of special interest (AESI) considered related to study vaccination|Frequency of new onset chronic medical conditions|Frequency overall and in each dosage group of serious adverse events (SAE) and adverse events of special interest (AESI) considered related to study vaccination|Frequency overall and in each dosage group of solicited injection site and systemic reactogenicity.|Frequency overall and in each dosage group of unsolicited vaccine-related adverse events (AE), including vaccine-related laboratory AE.|Severity overall and in each dosage group of solicited injection site and systemic reactogenicity.|Severity overall and in each dosage group of unsolicited vaccine-related adverse events (AE), including vaccine-related laboratory AE.|Type overall and in each dosage group of serious adverse events (SAE) and adverse events of special interest (AESI) considered related to study vaccination|Peak GMT overall and by dosage group as measured by ZIKV ELISA and neutralization assay.|Per visit GMT overall and by dosage group as measured by ZIKV ELISA and neutralization assay.|Proportion of subjects overall and by dosage group that seroconvert to ZIKV at each post-vaccination visit by assessing ELISA responses in comparison with baseline|Proportion of subjects overall and by dosage group that seroconvert to ZIKV at each post-vaccination visit by assessing neutralization titers in comparison with baseline","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 49 Years   (Adult)","Phase 1","91","NIH","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","16-0033|HHSN272200800003C","October 14, 2016","December 5, 2018","December 5, 2018","November 2, 2016",,"December 7, 2018","Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02952833"
12,"NCT03624946","Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)",,"Completed","No Results Available","Zika Virus Infection|Zika Virus Disease","Biological: Zika Virus Immune Globulin (ZIKV-IG)|Other: Placebo","Assessment of Zika Virus Immune Globulin (ZIKV-IG) safety (Number and severity of adverse events.)|Assessment of Zika Virus Immune Globulin (ZIKV-IG) Maximum Concentration (Cmax)|Assessment of Zika Virus Immune Globulin (ZIKV-IG) Time to Maximum Concentration (Tmax)|Assessment of Zika Virus Immune Globulin (ZIKV-IG) Area Under the Curve Up to Last Quantifiable Concentration (AUC0-t)|Assessment of Zika Virus Immune Globulin (ZIKV-IG) Area Under the Curve Extrapolated to Infinity (AUC0-inf)|Assessment of Zika Virus Immune Globulin (ZIKV-IG) Clearance (CL)|Assessment of Zika Virus Immune Globulin (ZIKV-IG) Half-Life (t1/2)|Assessment of Zika Virus Immune Globulin (ZIKV-IG) Volume of Distribution (Vz)","Emergent BioSolutions","All","18 Years to 55 Years   (Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","ZK-001","July 30, 2018","March 6, 2019","March 6, 2019","August 10, 2018",,"July 17, 2019","Syneos Health, Early Phase, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03624946"
13,"NCT03008122","Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic Area",,"Active, not recruiting","No Results Available","Zika Virus Infection","Other: Placebo|Biological: Zika Virus Purified Inactivated Vaccine (ZPIV)","Comparison of study withdrawals and discontinuation of study vaccination due to any reason between dosage groups and by pre-vaccination flavivirus immune status|Comparison of the duration of vaccine-related Grade 3 local, systemic, or laboratory AE, and Grade 2 or greater local or systemic reactogenicity between dosage groups and by pre-vaccination flavivirus immune status|Comparison of the frequency of vaccine-related Grade 3 local, systemic, or laboratory AE, and Grade 2 or greater local or systemic reactogenicity between dosage groups and by pre-vaccination flavivirus immune status|Comparison of the type of vaccine-related Grade 3 local, systemic, or laboratory AE, and Grade 2 or greater local or systemic reactogenicity between dosage groups and by pre-vaccination flavivirus immune status|Duration of serious adverse events (SAE) and adverse events of special interest (AESI) considered related to study vaccine|Frequency of new onset chronic medical conditions reported|Frequency of serious adverse events (SAE) and adverse events of special interest (AESI) considered related to study vaccine|Frequency of solicited injection site reactogenicity|Frequency of systemic reactogenicity|Frequency of unsolicited vaccine-related adverse events (AE), including vaccine-related laboratory AE|Severity of solicited injection site reactogenicity|Severity of systemic reactogenicity|Severity of unsolicited vaccine-related adverse events (AE), including vaccine-related laboratory AE|Type of serious adverse events (SAE) and adverse events of special interest (AESI) considered related to study vaccine|Frequency of seroconversion to ZIKV measured by neutralization assay in comparison with baseline sample|Frequency of seroconversion to ZIKV measured by ZIKV ELISA in comparison with baseline sample|Peak GMT as measured by neutralization assay|Peak GMT as measured by ZIKV ELISA|Per Visit GMT as measured by neutralization assay|Per Visit GMT as measured by ZIKV ELISA|Proportion of subjects with at least a 4-fold rise in ZIKV GMT as measured by ZIKV ELISA and neutralization assay compared with baseline overall","National Institute of Allergy and Infectious Diseases (NIAID)","All","21 Years to 49 Years   (Adult)","Phase 1","91","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","16-0034|HHSN272201300021I","February 24, 2017","August 2, 2021","August 2, 2021","January 2, 2017",,"February 21, 2020","Ponce School of Medicine CAIMED Center, Ponce, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT03008122"
14,"NCT03679728","Sensorimotor Outcomes of Children Exposed to Foetal Zika Virus Infection",,"Completed","No Results Available","Zika Virus Infection","Behavioral: First trimester|Behavioral: Second trimester","Children with microcephaly at birth, whose mothers had zika virus infection in the first or second gestation trimester, showed poor sensorimotor outcomes, mainly impaired muscle tone and antigravity postural control.|Children whose mothers were affected in the first trimester had lower head circumference measures that children whose mothers were affected in the second trimester.","University of Sao Paulo","All","6 Months to 18 Months   (Child)",,"31","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","65822017.3.0000.5390","August 2, 2016","September 15, 2016","April 16, 2017","September 20, 2018",,"September 20, 2018","School of Arts, Sciences and Humanities of the University of Sao Paulo, Sao Paulo, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT03679728"
15,"NCT02963909","A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.",,"Completed","No Results Available","Zika Virus Infection","Biological: IXIARO|Other: Placebo|Biological: YF Vax 17D Strain|Biological: Zika Virus Purified Inactivated Vaccine (ZPIV)","Occurrence of SAEs, new onset medical conditions, and AESIs|Occurrence of solicited local AEs|Occurrence of solicited systemic AEs|Occurrence of unsolicited AEs|Relationship of unsolicited AEs to vaccination|Severity of solicited local AEs|Severity of solicited systemic AEs|Severity of unsolicited AEs|Anti- ZIKV NAbs GMTs by group in subjects who consent to two doses of ZPIV|Anti- ZIKV NAbs GMTs overall|Anti- ZIKV NAbs seroconversion rates by group in subjects who consent to two doses of ZPIV|Anti- ZIKV NAbs seroconversion rates overall|Anti-ZIKV Nabs GMTs for group 1 subjects who consent to the third dose of ZPIV|Anti-ZIKV Nabs GMTs for group 2 and 3 subjects who consent to the third dose of ZPIV|Anti-ZIKV Nabs seroconvertion rates for group 1 subjects who consent to the third dose of ZPIV|Anti-ZIKV Nabs seroconvertion rates for group 2 and 3 subjects who consent to the third dose of ZPIV","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 49 Years   (Adult)","Phase 1","75","NIH","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","16-0062","November 1, 2016","October 30, 2018","October 30, 2018","November 15, 2016",,"November 9, 2018","Walter Reed Army Institute of Research - Clinical Trials Center, Silver Spring, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02963909"
16,"NCT03425149","Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults",,"Completed","No Results Available","Zika Virus|Zika Virus Infection","Biological: VLA1601|Biological: Placebo","Rate of subjects with solicited adverse events including injection site and systemic reactions|Rate of subjects with any adverse events (AEs)|Rate of subjects with serious adverse events (SAEs)|Rate of subjects with any IMP-related AEs|Rate of subjects with any IMP-related SAEs|Geometric mean titer (GMT) for ZIKV-specific neutralizing antibody titer after last active vaccination|GMT for ZIKV-specific neutralizing antibody titer after first vaccination|Rate of subjects with seroconversion after last active vaccination|Rate of subjects with seroconversion after first vaccination|Fold increase of ZIKV-specific neutralizing antibody titers after last active vaccination as compared to baseline|Fold increase of ZIKV-specific neutralizing antibody titers after first vaccination as compared to baseline","Valneva Austria GmbH|Emergent BioSolutions","All","18 Years to 49 Years   (Adult)","Phase 1","67","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","VLA1601-101","February 24, 2018","June 26, 2018","November 16, 2018","February 7, 2018",,"July 5, 2019","New Orleans Center for Clinical Research, Knoxville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03425149"
17,"NCT02840487","Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults",,"Completed","No Results Available","Prevention of Zika Infection|Zika-Specific Immune Response","Biological: VRC-ZKADNA085-00-VP","To evaluate the safety and tolerability of four vaccination regimens with ZIKV DNA vaccine (VRC-ZKADNA085-00-VP) administered IM at 4 mg.|To evaluate the magnitude and frequency of ZIKV-specific antibodyresponse as measured by neutralization assay.","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years to 35 Years   (Adult)","Phase 1","80","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","160148|16-I-0148","August 2, 2016","March 14, 2019","March 14, 2019","July 21, 2016",,"March 18, 2019","Hope Clinic - Emory Vaccine Ctr, Decatur, Georgia, United States|University of Maryland Ctr. for Vaccine Development, Baltimore, Maryland, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02840487"
18,"NCT03014089","Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects",,"Completed","No Results Available","Zika Virus","Biological: mRNA-1325|Other: Placebo","Types, frequency, and severity of serious adverse events (SAE), adverse events of special interest (AESI) and adverse events considered related to study drug|Frequency of seroconversion to ZIKV measured by neutralization assay in comparison with baseline sample","ModernaTX, Inc.|Biomedical Advanced Research and Development Authority","All","18 Years to 49 Years   (Adult)","Phase 1","90","Industry|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","mRNA-1325-P101|HHSO100201600029C","December 21, 2016","July 2019","July 2019","January 9, 2017",,"December 9, 2019","San Diego, California, United States|Melbourne, Florida, United States|Peoria, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03014089"
19,"NCT02996461","VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, inHealthy Adults",,"Completed","No Results Available","Prevention of Zika Infection|Zika-Specific Immune Response","Biological: VRC-ZKADNA090-00-VP","To evaluate the safety and tolerability of v ZIKV DNA vaccine administered at 4mg IM by needle and syringe.|To evaluate the safety and tolerability of ZIKV DNA vaccine administered at 4 mg IM by Pharma jet.|To evaluate the magnitude and the frequency of ZIKV-specific antibody response as measured by neutralization assay.","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years to 50 Years   (Adult)","Phase 1","45","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","170024|17-I-0024","December 12, 2016","September 3, 2019","September 3, 2019","December 19, 2016",,"December 17, 2019","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02996461"
20,"NCT02856984","Zika in Infants and Pregnancy (ZIP)",,"Active, not recruiting","No Results Available","Zika Virus Disease (Disorder)",,"Incidence of congenital malformations for ZIKV infected participants|Incidence of adverse fetal outcomes for ZIKV infected participants|Incidence of congenital malformations for ZIKV symptomatic participants|Incidence of adverse fetal outcomes for ZIKV symptomatic participants","RTI International|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Environmental Health Sciences (NIEHS)|Oswaldo Cruz Foundation","Female","15 Years and older   (Child, Adult, Older Adult)",,"6461","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","GN ZIKA","June 2016","May 31, 2020","May 31, 2020","August 5, 2016",,"January 6, 2020","Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz/MS; Rue Waldemar Falcao, Salvador, Bahia, Brazil|Departamento de Medicina Tropical da Universidade Federal de Pernambuco-UFPE, Recife, PE, Brazil|Instituto Fernandes Figueira - FIOCRUZ, Rio de Janeiro, RJ, Brazil|Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes, 3900 - Monte Alegre, Ribeirão Preto, SP, Brazil|Universidad de Antioquia, Medellín, Colombia|Fundación para la Alimentación y Nutrición de Centro América y Panamá (INCAP), Guatemala, Guatemala|MINSA Central, Managua, Nicaragua|Universidad Peruana, Lima, Peru|University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico|University of Puerto Rico - Recinto de Río Piedras, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT02856984"
21,"NCT02810210","Zika Virus Infection's Neonatal and Pediatric Consequences in French Department of America","ZIKA-DFA-BB","Unknown status","No Results Available","Zika Virus Infection on Fetus and Child During the Pregnancy","Other: fundus examination|Other: Head ultrasound","Embryofoetopathy incidence within cohort 1 and 3|Comparison of congenital abnormality incidence rates between cohorts 1 and 3","Institut National de la Santé Et de la Recherche Médicale, France","All","up to 2 Years   (Child)",,"2220","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","C16-19","June 2016","September 2017","September 2018","June 22, 2016",,"August 30, 2016","CH de la Basse Terre, Basse-terre Cedex, France|CH Andrée Rosemon (CHAR), Cayenne Cedex, France|CHU de Martinique, Fort de France Cedex, France|CHU de Pointe à Pitre/Les Abymes, Pointe A Pitre, France|CH LC Fleming, Saint Martin Cedex, France|CH de l'Ouest Guyanais Franck Joly (CHOG), Saint-laurent-du-maroni, France",,"https://ClinicalTrials.gov/show/NCT02810210"
22,"NCT03263195","Prospective Cohort Study of HIV and Zika in Infants and Pregnancy","HIV ZIP","Active, not recruiting","No Results Available","HIV|Zika Virus|Pregnant Women",,"Enrollment (150 HIV-infected and 50 HIV-uninfected pregnant women within one year, with a minimum of 20 of these women having HIV/ZIKV co-infection by their end of pregnancy).|Viral suppression (in HIV-infected women with ZIKV co-infection compared to those without ZIKV co-infection during pregnancy and at the time of delivery).|Incidence of ZIKV infection (among pregnant women with HIV infection compared to those without HIV infection).|Incidence of adverse pregnancy outcomes (in women co-infected with HIV and ZIKV, women infected with either HIV or ZIKV alone, and doubly uninfected women).|Incidence of vertical transmission of HIV and ZIKV (in women co-infected with HIV and ZIKV and women infected with either HIV or ZIKV alone).|Incidence of congenital malformations (among offspring of women co-infected with HIV and ZIKV, women infected with either HIV or ZIKV alone, and doubly uninfected women).|Incidence of other adverse outcomes among offspring of women co-infected with HIV and ZIKV, women infected with either HIV or ZIKV alone.|Growth, as measured by length, weight, and head circumference (among children with in utero exposure to HIV and ZIKV, in utero exposure to either HIV or ZIKV alone, and no in utero exposure to either virus).|Audiologic function as assessed by hearing levels, acoustic immitance, and otoacoustic emissions (among children with in utero exposure to HIV and ZIKV, in utero exposure to either HIV or ZIKV alone, and no in utero exposure to either virus).|Ophthalmologic structure and function as assessed by ophthalmoscopy, fixation, and acuity card testing (among children with in utero exposure to HIV and ZIKV, in utero exposure to either HIV or ZIKV alone, and no in utero exposure to either virus).|Neurodevelopment as assessed by the Bayley III and Ages and Stages Questionnaires- 3rd Edition (among children with in utero exposure to HIV and ZIKV, in utero exposure to either HIV or ZIKV alone, and no in utero exposure to either virus).","Westat|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)","Female","15 Years and older   (Child, Adult, Older Adult)",,"395","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","HIV-ZIP","August 23, 2017","August 2020","August 2020","August 28, 2017",,"February 5, 2020","University of Miami Pediatric/Prenatal HIV/AIDS, Miami, Florida, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Baylor College of Medicine; Texas Children's Hospital, Houston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|University of Sao Paulo at Riberaio Preto Brazil, São Paulo, Brazil|University of Puerto Rico Pediatrics HIV/AIDS Research Program, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT03263195"
23,"NCT03393286","ZIKAlliance Children Cohort (ZIKAllianceCH)","ZIKAllianceCH","Recruiting","No Results Available","Zika Virus",,"Congenital Abnormalities detected after birth as defined by the evolving definition of the congenital zika syndrome|Hearing abnormalities measured after birth|Visual abnormalities measured after birth|Developmental / cognitive abnormalities measured by the Ages and Stages 3rd Edition (ASQ3)|Developmental / cognitive abnormalities measured by the Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III)","University of Heidelberg Medical Center","All","up to 6 Months   (Child)",,"5000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","734548CH (EC   H2020   RIA)","January 15, 2018","September 30, 2019","September 30, 2020","January 8, 2018",,"May 10, 2019","Sosecali Ltd. (SOSE), Guaqui, Bolivia|Fundacao Oswaldo Cruz (FIOCRUZ), Recife, Brazil|Fundacao Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil|University of Sao Paulo, São Paulo, Brazil|Industrial University of Santander (UIS), Bucaramanga, Colombia|Pedro Kouri Institute (IPK), Havana, Cuba|INSERM, Pointe-à-Pitre, Guadeloupe|IMSS Mexico (IMSS), Guadalajara, Mexico|National Institute of Public Health (INSP), Mérida, Mexico|Universidad de Carabobo / UMC Groningen (UMCG), Valencia, Venezuela",,"https://ClinicalTrials.gov/show/NCT03393286"
24,"NCT02733796","Persistence of Zika Virus in Semen After Acute Infection",,"Active, not recruiting","No Results Available","Zika Virus|Zika Virus Disease|Virus Shedding|Transmission",,"Incidence rate of ZIKV persistence in semen|kinetics of ZIKV persistence in semen|replication fitness of ZIKV in semen|comparison of ZIKV sequences from semen vs. non-semen samples","Institute of Tropical Medicine, Belgium","Male","18 Years to 80 Years   (Adult, Older Adult)",,"15","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","B300201628191","March 2016","January 2019","January 2019","April 12, 2016",,"April 12, 2018","ITM, Antwerp, Belgium",,"https://ClinicalTrials.gov/show/NCT02733796"
25,"NCT03330600","Efficacy of Aquatic Physiotherapy in Children With Microcephaly by Zika Virus Congenital Syndrome",,"Completed","No Results Available","Zika Virus Infection|Microcephaly","Behavioral: aquatic physicotherapy|Behavioral: immersion","change in Modified Tardieu Scale|change in heart rate|change in respiratory frequency|change in oxygen saturation|change in body temperature","Universidade Federal de Pernambuco","All","3 Months to 24 Months   (Child)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Projeto Milena LEPed","June 1, 2017","February 18, 2018","October 30, 2018","November 6, 2017",,"May 7, 2019","Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil",,"https://ClinicalTrials.gov/show/NCT03330600"
26,"NCT02916732","Zika Virus Infection's Pregnancy Consequences in French Department of America","ZIKA-DFA-FE","Unknown status","No Results Available","Incidence of ZIKV Infection on Fetus During the Pregnancy",,"Incidence of ZIKV infection during pregnancy|Incidence of microcephaly and other fetal abnormalities","Institut National de la Santé Et de la Recherche Médicale, France","Female","18 Years to 60 Years   (Adult)",,"26980","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","C16-08|2016-A00399-42","April 2016","January 2018","January 2019","September 27, 2016",,"September 27, 2016","CH Andrée Rosemon (CHAR), Cayenne Cedex, France|CHU de Martinique, Fort de France Cedex, France|CHU de Pointe à Pitre/Les Abymes, Pointe A Pitre, France|CH de l'Ouest Guyanais Franck Joly (CHOG), Saint-laurent-du-maroni, France",,"https://ClinicalTrials.gov/show/NCT02916732"
27,"NCT03443830","Safety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in Humans",,"Completed","No Results Available","Treatment of Acute Zika Virus Infection","Drug: Tyzivumab","Incidence of Treatment-Emergent Adverse Event (Safety and Tolerability)|Maximum Concentration (Cmax) - Pharmacokinetic Assessment|Time to Maximum Concentration (Tmax) - Pharmacokinetic Assessment|Area Under the Curve Extrapolated to Infinity (AUC0-∞) - Pharmacokinetic Assessment|AUC calculated from time of administration to the last measurable concentration (AUC0-last) - Pharmacokinetic Assessment|Half-Life (t1/2) - Pharmacokinetic Assessment|Volume of Distribution (Vd) - Pharmacokinetic Assessment|Clearance [CL] - Pharmacokinetic Assessment|Anti-Drug Antibody Assessment","Tychan Pte Ltd.|Duke-NUS Graduate Medical School|Singapore Clinical Research Institute|National University, Singapore|National University Hospital, Singapore","All","21 Years to 45 Years   (Adult)","Phase 1","24","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ZKT-001","February 8, 2018","September 12, 2018","December 4, 2018","February 23, 2018",,"April 10, 2019","SingHealth Investigational Medicine Unit, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT03443830"
28,"NCT03255369","Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment (ZIKVIRUSIFF)","ZIKVIRUSIFF","Unknown status","No Results Available","ZIKA VIRUS INFECTION|Child Development|Microcephaly","Other: Child exposed Zika virus proved","Microcephaly and/or delay in development|ocular injury and cognitive disorder in Bayley Test 3rd edition|Hearing injury and language delay in Bayley Test 3rd edition","Oswaldo Cruz Foundation|Conselho Nacional de Desenvolvimento Científico e Tecnológico|Rio de Janeiro State Research Supporting Foundation (FAPERJ)","All","up to 3 Years   (Child)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","52675616.0.0000.5269","January 2, 2016","December 30, 2018","December 30, 2019","August 21, 2017",,"May 3, 2018","Instituto Fernandes Figueira/Fiocruz, Rio de Janeiro, RJ, Brazil",,"https://ClinicalTrials.gov/show/NCT03255369"
29,"NCT03776695","Safety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in ZIKV Infected Patients",,"Recruiting","No Results Available","Treatment of Acute Zika Virus Infection","Biological: Tyzivumab|Other: Placebo","Incidence of Treatment-Emergent Adverse Event (Safety and Tolerability)|Viral Clearance Post-Tyzivumab Infusion (Efficacy)","Tychan Pte Ltd.|Singapore Clinical Research Institute|Duke-NUS Graduate Medical School","All","21 Years to 60 Years   (Adult)","Phase 1","28","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","ZKT-002|CTA1800062","October 9, 2018","December 31, 2020","December 31, 2020","December 17, 2018",,"December 17, 2018","SingHealth Investigational Medicine Unit, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT03776695"
30,"NCT04015648","Safety and Immunogenicity of a Candidate ZIKV Vaccine (ZIKA001)",,"Recruiting","No Results Available","Zika|Chikungunya","Biological: ChAdOx1 Zika|Biological: ChAdOx1 Zika, ChAdOx1 Chik","Safety and tolerability of ChAdOx1 Zika given as a standalone vaccine or co-administered with ChAdOx1 Chik at different doses in healthy adult volunteers assessed by the occurrence of solicited adverse events.|Safety and tolerability of ChAdOx1 Zika given as a standalone vaccine or co-administered with ChAdOx1 Chik at different doses in healthy adult volunteers assessed by the occurrence of unsolicited adverse events.|Safety and tolerability of ChAdOx1 Zika given as a standalone vaccine or co-administered with ChAdOx1 Chik at different doses in healthy adult volunteers assessed by the occurrence of serious adverse events.|Safety and tolerability of ChAdOx1 Zika given as a standalone vaccine or co-administered with ChAdOx1 Chik at different doses in healthy adult volunteers assessed by the occurrence of laboratory adverse events.|Measures of humoral immunogenicity to the ChAdOx1 ZIKA and ChAdOx1 CHIK vaccines|Measures of cellular immunogenicity to the ChAdOx1 ZIKA and ChAdOx1 CHIK vaccines","University of Oxford","All","18 Years to 50 Years   (Adult)","Phase 1","57","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ZIKA001","October 21, 2019","July 1, 2021","July 1, 2021","July 11, 2019",,"January 9, 2020","CCVTM, University of Oxford, Churchill Hospital, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04015648"
31,"NCT03188731","ZIKAlliance Pregnant Women Cohort","ZIKAlliancePW","Active, not recruiting","No Results Available","Zika Virus|Pregnancy Related",,"Congenital Abnormalities","University of Heidelberg Medical Center|European Union|ZIKAlliance|Oswaldo Cruz Foundation|University of Sao Paulo|London School of Hygiene and Tropical Medicine|Federal University of Bahia|Universidade Federal de Goias|University Medical Center Groningen|University of Carabobo|Universidad Industrial de Santander|Sosecali Hospital, Guyaquil|Tropical Medicine Institute Pedro Kourí, Cuba|Mexican National Institute of Public Health|Instituto Mexicano del Seguro Social|Institut National de la Santé Et de la Recherche Médicale, France|Erasmus Medical Center","Female","16 Years to 45 Years   (Child, Adult)",,"5000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","734548PW (EC   H2020   RIA)","May 24, 2017","September 30, 2019","September 30, 2020","June 15, 2017",,"September 30, 2019","Sosecali Ltd. (SOSE), Guaqui, Bolivia|INSERM, Santa Cruz, Bolivia|Federal University of Bahia (UFB), Bahia, Brazil|Universidade Federal de Minas Gerais, Belo Horizonte, Brazil|Federal University of Goias, Goiás, Brazil|Fundacao Oswaldo Cruz (FIOCRUZ), Recife, Brazil|Fundacao Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil|University of Sao Paulo, São Paulo, Brazil|Industrial University of Santander (UIS), Bucaramanga, Colombia|Pedro Kouri Institute (IPK), Havana, Cuba|INSERM, Pointe-à-Pitre, Guadeloupe|IMSS Mexico (IMSS), Guadalajara, Mexico|National Institute of Public Health (INSP), Mérida, Mexico|Universidad de Carabobo / UMC Groningen (UMCG), Valencia, Venezuela",,"https://ClinicalTrials.gov/show/NCT03188731"
32,"NCT02831699","The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico","Zik01","Completed","No Results Available","Zika Virus Disease (Disorder)|Dengue|Chikungunya",,"The proportion of subjects that have confirmed Zika, Chikungunya, or Dengue (including co-infections) from the subjects presenting with fever and/or rash in southeastern Mexico.","Mexican Emerging Infectious Diseases Clinical Research Network|Secretaria de Salud, Mexico|National Institute of Allergy and Infectious Diseases (NIAID)","All","1 Year and older   (Child, Adult, Older Adult)",,"600","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","Zik01","June 21, 2016","January 25, 2019","January 25, 2019","July 13, 2016",,"December 20, 2019","Hospital General de Tapachula, Tapachula, Chiapas, Mexico|Hospital Regional de Alta Especialidad Ciudad Salud, Chiapas, Mexico|Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE) Clínica Hospital Dr. Roberto Nettel Flores, Chiapas, Mexico|Instituto Mexicano del Seguro Social (IMSS) Delegación Estatal / Hospital General de Zona con Medicina Familiar No. 1, Chiapas, Mexico|Instituto Mexicano del Seguro Social (IMSS) Delegación Estatal / Unidad de Medicina Familiar No. 11, Chiapas, Mexico|Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico",,"https://ClinicalTrials.gov/show/NCT02831699"
33,"NCT03161444","Estimated Cumulative Incidence of Zika Infection at the End of the First Epidemic in the French West Indies in a Sample of Patients Followed for HIV Infection.","ZIKAVIH","Recruiting","No Results Available","HIV Infections|Zika Virus Infection","Other: Biological sample collection","Presence or not of Zika virus-specific immunoglobulin G antibodies in the serum taken after the epidemic|Existence or not of clinical signs evocating of an episode of disease with Zika virus.|Presence or not of Dengue virus specific antibodies before the outbreak of Zika virus infection, sought on the samples taken at the end of the chikungunya epidemic.|Presence or not of Chikungunya-specific antibodies before the outbreak of Zika virus infection, sought after sampling at the end of the chikungunya epidemic.|Evolution of the CD4 lymphocyte levels before and after the outbreak of Zika virus|Evolution of the HIV1 RNA levels before and after the outbreak of Zika virus","University Hospital Center of Martinique|University Hospital of Guadeloupe","All","18 Years and older   (Adult, Older Adult)","Not Applicable","362","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","16/B/06|2016-A01173-48","March 21, 2017","July 2018","December 2018","May 19, 2017",,"March 20, 2018","University Hospital of Martinique, Fort-de-France, France|University Hospital of Guadeloupe, Pointe-à-Pitre, Guadeloupe",,"https://ClinicalTrials.gov/show/NCT03161444"
34,"NCT03204409","ZIKAlliance Natural History Study","ZIKAllianceNH","Suspended","No Results Available","Zika Virus|Zika Virus Infection",,"ZIKA Virus Infection|DENGUE Virus Infection|Chikungunya Virus Infection","University of Heidelberg Medical Center|University of Sao Paulo","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","734548NH (EC   H2020   RIA)","April 1, 2018","December 31, 2019","September 3, 2020","July 2, 2017",,"April 18, 2019","University of Sao Paulo, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT03204409"
35,"NCT03343626","Safety, Immunogenicity and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Adult Participants",,"Active, not recruiting","No Results Available","Virus, Zika|Zika Virus Disease|Flavivirus Infections|Healthy Participants","Drug: Placebo|Biological: PIZV","Percentage of Participants With Solicited Local Injection Site Reactions Within 7 Days After Dose 1 of PIZV or Placebo|Percentage of Participants With Solicited Local Injection Site Reactions Within 7 Days After Dose 2 of PIZV or Placebo|Percentage of Participants With Solicited Systemic Adverse Events (AEs) Within 7 Days After Dose 1 of PIZV or Placebo|Percentage of Participants With Solicited Systemic AEs Within 7 Days After Dose 2 of PIZV or Placebo|Percentage of Participants who Experience at Least one Non-serious Unsolicited AE Within 28 Days After Dose 1 of PIZV or Placebo|Percentage of Participants who Experience at Least one Non-serious Unsolicited AE Within 28 Days After Dose 2 of PIZV or Placebo|Percentage of Participants who Experience at Least one Serious Adverse Event (SAE) Within 28 Days After Dose 1 of PIZV or Placebo|Percentage of Participants who Experience at Least one Serious Adverse Event (SAE) Within 28 Days After Dose 2 of PIZV or Placebo|Geometric Mean Neutralizing Antibody Titers (GMTs) of Zika Virus (ZIKV) 28 Days After Dose 2 of PIZV or Placebo|Percentage of Participants who Experience at Least one SAE During the Study|Geometric Mean Neutralizing Antibody Titers (GMTs) of ZIKV 28-days After Dose 1, 6, 12 and 24-months After Dose 2 in Applicable Groups|Seropositivity Rate for PIZV 28 Days After Dose 1, 28 Days After Dose 2, 6 Months, 12 Months and 24 Months After Dose 2 in Applicable Groups|Seroconversion Rate for PIZV 28 Days Post Dose 1 and 2","Takeda","All","18 Years to 49 Years   (Adult)","Phase 1","271","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","ZIK-101|U1111-1201-5778","November 13, 2017","December 28, 2018","November 19, 2020","November 17, 2017",,"March 26, 2019","Clinical Research of South Florida, Coral Gables, Florida, United States|Miami Research Associates, Miami, Florida, United States|AppleMed Research, Miami, Florida, United States|Johnson County Clin-Trials, Lenexa, Kansas, United States|Regional Clinical Research Inc., Endwell, New York, United States|Rochester Clinical Research, Rochester, New York, United States|Tekton Research, Austin, Texas, United States|Puerto Rico Clinical and Translational Research Consortium, San Juan, Puerto Rico|Ponce Medical School Foundation, Santurce, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT03343626"
36,"NCT03227601","Effect of a Posture Adapter for 12 to 24-month Children With Zyka Virus Syndrome",,"Unknown status","No Results Available","Zika Virus","Device: posture adapter","Body Alignment|Motor function|Gastrointestinal function|Muscular tonus","Universidade Federal de Pernambuco","All","12 Months to 24 Months   (Child)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1808","July 20, 2017","October 19, 2017","August 31, 2018","July 24, 2017",,"July 24, 2017","Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil",,"https://ClinicalTrials.gov/show/NCT03227601"
37,"NCT02794181","Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)",,"Completed","No Results Available","Zika Virus|Dengue Virus|Chikungunya Virus Infections",,"Prevalence of ZIKV, DENV and CHIKV infection (RNA-positives) among travel-deferred adult blood donors in the study population.|Prevalence of ZIKV infection (RNApositives) among adult blood donors with a history of potential sexual exposure to ZIKV infection, in the study population.|24-week Natural History of ZIKV, DENV and CHIKV (RNA-positives).","National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"34","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","160124|16-CC-0124","June 8, 2016","March 14, 2019","March 14, 2019","June 9, 2016",,"March 18, 2019","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02794181"
38,"NCT04118738","International Cohort Study of Children Born to Women Infected With Zika Virus During Pregnancy",,"Recruiting","No Results Available","Zika|Neurodevelopmental Abnormality|Hearing Loss|Growth Delay|Eye Abnormalities",,"Neurodevelopmental outcome at age18 months|Neurodevelopmental outcome at age 24 months|Neurodevelopmental outcome at age 30 months|Neurodevelopmental outcome at age 36 months|Neurodevelopmental outcome at age 42 months|Anthropometric Measurements: Height|Anthropometric Measurements: Weight|Anthropometric Measurements: Head circumference|Anthropometric Measurements: Mid upper arm circumference|Hearing assessment by Otoacustic Emissions (OAE) and Visual Reinforcement Audiometry (VRA)|Comprehensive ophthalmologic evaluation.","Westat|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)|Oswaldo Cruz Foundation (Fiocruz)","All","18 Months to 42 Months   (Child)",,"400","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","ZIP 2.0","June 12, 2019","July 2021","July 2021","October 8, 2019",,"October 8, 2019","Departamento de Medicina Tropical da Universidade Federal de Pernambuco- UFPE, Recife, Pernambuco, Brazil|Instituto Fernandes Figueira - FIOCRUZ, Rio De Janeiro, Brazil|Asociación Civil Selva Amazónica, Iquitos, Loreto, Peru|Puerto Rico Medical Center- Maternal Infant Studies Center (CEMI), San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT04118738"
39,"NCT03776903","Evaluation of the Clinical Performance of the ZIKV Detect™ 2.0 IgM Capture ELISA",,"Completed","No Results Available","Zika Virus Infection","Other: ZIKV Detect™ 2.0 IgM Capture ELISA","Positive Percent Agreement and Negative Percent Agreement|Duration of Positive Percent Agreement","InBios International, Inc.|Fast-Track Drugs & Biologics, LLC|Biomedical Advanced Research and Development Authority","All","Child, Adult, Older Adult",,"600","Industry|Other|U.S. Fed","Observational","Observational Model: Cohort|Time Perspective: Other","ZIKV-2016-01","April 1, 2018","August 31, 2018","September 30, 2018","December 17, 2018",,"December 17, 2018","InBios International, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03776903"
40,"NCT02874456","Pilot Study to Detect Zika Virus in Sperm","ZIKSPERM","Completed","No Results Available","Viruses","Other: virus detection","presence of Zika virus on RNA by polymerase chain reaction","University Hospital, Toulouse|Centre Hospitalier Universitaire de Pointe-a-Pitre|Institut Pasteur","Male","18 Years to 45 Years   (Adult)","Not Applicable","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","RC31/16/7941","May 6, 2016","December 2017","December 2017","August 22, 2016",,"July 19, 2019","University Hospital, Pointe-à-Pitre, Guadeloupe",,"https://ClinicalTrials.gov/show/NCT02874456"
41,"NCT02943304","Neurodevelopment Outcome of Newborns Exposed to Zika Virus (ZIKV) in Utero","ZEN Iniciative","Recruiting","No Results Available","Microcephaly|Mental Retardation","Other: Symptomatic pregnant women with positive RT-PCR ZIKV in serum or urine, or a positive serologic test specific for ZIKV","Neurodevelopmental Outcome|Fetal CNS Impairment","Universidad Industrial de Santander|University of North Carolina, Chapel Hill|Michigan State University","Female","13 Years to 50 Years   (Child, Adult)",,"440","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","4110","May 2016","December 2019","December 2020","October 24, 2016",,"January 17, 2019","Hospital Universitario de Santander, Bucaramanga, Santander, Colombia",,"https://ClinicalTrials.gov/show/NCT02943304"
42,"NCT03110770","VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents","DNA","Completed","No Results Available","Zika Virus|Zika Virus Infection|Virus Diseases|Flavivirus Infections|Flaviviral Diseases|Flaviviridae Infections|RNA Virus Infections","Biological: VRC-ZKADNA090-00-VP|Other: VRC-PBSPLA043-00-VP","Local Reactogenicity (Part A and B)|Systemic Reactogenicity (Part A and B)|Laboratory measures (Part A)|Laboratory measures (Part B)|Serious adverse events (Part A)|Serious adverse events (Part B)|New chronic medical conditions (Part A)|New chronic medical conditions (Part B)|Confirmed cases of Dengue virus infection (Part A)|Confirmed cases of Dengue virus infection (Part B)|Unsolicited adverse events (Part A and B)|Confirmed cases of Zika with symptoms (Part B only)|Antibody response to VRC-ZKADNA090-00-VP (Part A and B)|Confirmed cases of Zika (Part B only)","National Institute of Allergy and Infectious Diseases (NIAID)|The Emmes Company, LLC|Leidos Biomedical Research, Inc.|FHI Clinical, Inc.|PPD","All","15 Years to 35 Years   (Child, Adult)","Phase 2","2338","NIH|Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","VRC 705","March 29, 2017","October 4, 2019","October 4, 2019","April 12, 2017",,"December 24, 2019","QPS-Miami Research Associates, Miami, Florida, United States|Doctors Hospital at Renaissance, Edinburg, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Hospital Das Clinicas Da Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil|Centro de Pesquisas Clínicas Do Instituto Central Do Hospital Das Clínicas Da FMUSP, São Paulo, SP, Brazil|Clinica de la Costa Ltda, Barranquilla, Atlantico, Colombia|Centro de Atencion y Diagnostico de Enfermedades Infecciosas, Bucaramanga, Santander, Colombia|CCIM Costa Rican Center Center of Medical Research, Sociedad Anonima, San José, Los Yoses, Costa Rica|AGA Clinical Centro de Investigaciones, Guayaquil, Guayas, Ecuador|Hospital Civil Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico|Instituto Conmemorativo Gorgas, Panamá, San Miguelito Province, Panama|Asociacion Civil Selva Amazonica, Iquitos, Maynas/Loreto, Peru|Unidad de Ensayos (UNIDEC) del Policlinico Universidad Nacional Mayor de San Marcos, Lima, Peru|Ponce Medical School Foundation Inc./CAIMED Center, Ponce, Puerto Rico|Fundación de Investigación de Diego, San Juan, Puerto Rico|San Juan Hospital Research Unit, San Juan, Puerto Rico|Puerto Rico Clinical and Translational Research Consortium, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT03110770"
43,"NCT03922594","Surveillance of Zika-related Microcephaly in Sub-Saharan Africa and Asia",,"Recruiting","No Results Available","Microcephaly|Congenital Infection","Diagnostic Test: Differential diagnosis for infectious causes of microcephaly","Incidence of microcephaly (per 10,000 live births)|Proportion of microcephaly attributable to ZIKV|Proportion of microcephaly linked to other infectious etiologies","Institut Pasteur|Centre Pasteur du Cameroun|Guangzhou Women and Children's Medical Center|Institut Pasteur de Côte d'Ivoire|Institut Pasteur Ho Chi Minh City|Tu Du Hospital|Perinatal Society of Sri Lanka|University of Colombo|University of Lausanne|University of Lausanne Hospitals|The University of Hong Kong|Ministry of Health of Sri Lanka|Central Hospital Maternity|Essos Hospital Center|Guangzhou Baiyun Maternal and Child Health Hospital|General Hospital of Yopougon-Attie|General Hospital Abobo-Sud|Castle Street Hospital for Women|De Soyza Hospital for Women","All","up to 2 Days   (Child)",,"125","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ZIKA_2016-102","May 20, 2019","June 2021","June 2021","April 22, 2019",,"June 25, 2019","Central Hospital Maternity, Yaoundé, Cameroon|Essos Hospital Centre Maternity, Yaoundé, Cameroon|Guangzhou Women's and Children's Hospital, Guangzhou, China|General Hospital Abobo-Sud, Abidjan, Côte D'Ivoire|General Hospital of Yopougon-Attie, Abidjan, Côte D'Ivoire|Castle Street Hospital for Women, Colombo, Sri Lanka|De Soyza Hospital for Women, Colombo, Sri Lanka|Tu Du Hospital, Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT03922594"
44,"NCT03037164","INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections","RedeS","Recruiting","No Results Available","Anemia","Device: INTERCEPT Blood System for Red Blood Cells|Device: Conventional (Control)","Adjusted hemoglobin increment averaged over multiple transfusions|Adverse Events|Treatment emergent antibodies|Adjusted hemoglobin consumption|Transfusion reactions|RBC allo-antigens|Mortality","Cerus Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 3","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLI 00126","May 11, 2017","June 30, 2020","December 30, 2020","January 31, 2017",,"July 12, 2019","Mayo Clinic Jacksonville, Jacksonville, Florida, United States|OneBlood, Orlando, Florida, United States|Baylor St. Luke's Medical Center, Houston, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Menonita General Hospital, Aibonito, Puerto Rico|HIMA San Pablo Hospital, Caguas, Puerto Rico|San Juan Bautista School of Medicine Clinical Research Unit, Caguas, Puerto Rico|Banco de Sangre de Servicios Mutuos, Inc. (BSSM), Guaynabo, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT03037164"
45,"NCT02887482","Study of GLS-5700 in Dengue Virus Seropositive Adults",,"Completed","No Results Available","Healthy|Zika","Biological: GLS-5700|Biological: Placebo","Mean change from baseline in safety laboratory measures|Incidence of solicited adverse events after vaccination|Incidence of unsolicited adverse events after vaccination|Incidence of serious adverse events|Binding antibody titers to Zika envelope|Neutralizing antibody response against Zika virus|T cell response|Mean change from baseline for safety measures and adverse events","GeneOne Life Science, Inc.|Inovio Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","160","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Zika-002","August 2016","October 2017","June 2018","September 2, 2016",,"December 5, 2018","Clinical Research of Puerto Rico, San Juan, Puerto Rico|Fundacion De Investigation, San Juan, Puerto Rico|University of Puerto Rico, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT02887482"
46,"NCT01386424","Screening for LID Clinical Studies Unit Healthy Volunteer Protocols",,"Recruiting","No Results Available","Zika|Influenza",,"Find Healthy volunteers for research","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)",,"5000","NIH","Observational","Observational Model: Other|Time Perspective: Prospective","110183|11-I-0183","July 20, 2011",,,"July 1, 2011",,"February 20, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01386424"
47,"NCT03055585","Applying Wolbachia to Eliminate Dengue","AWED","Recruiting","No Results Available","Dengue|Zika Virus Infection|Chikungunya Fever","Biological: Wolbachia-infected Aedes aegypti mosquitoes|Other: standard practice dengue control","Dengue incidence rate ratio in Wolbachia-treated versus untreated clusters|Zika incidence rate ratio in Wolbachia-treated versus untreated clusters|Chikungunya incidence rate ratio in Wolbachia-treated versus untreated clusters","Gadjah Mada University|Monash University|The Tahija Foundation","All","3 Years to 45 Years   (Child, Adult)","Not Applicable","10000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","UGM_KE/FK/105/EC","November 8, 2017","December 2019","December 2019","February 16, 2017",,"June 4, 2018","Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, DIY, Indonesia",,"https://ClinicalTrials.gov/show/NCT03055585"
48,"NCT02741882","Zika and Microcephaly: Case-control Study",,"Completed","No Results Available","Microcephaly","Other: Questionary","Zika virus infection clinical outcomes during pregnancy|zika virus serology|Chikungunya virus serology|Dengue virus serology","Laboratório Sabin","Female","16 Years and older   (Child, Adult, Older Adult)",,"110","Industry","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","Zika and microcephaly","February 2016","August 2016","February 2017","April 18, 2016",,"February 23, 2017","Sabin laboratory, Brasilia, Distrito Federal, Brazil",,"https://ClinicalTrials.gov/show/NCT02741882"
49,"NCT01099852","Cohort of Patients Infected by an Arbovirus","CARBO","Recruiting","No Results Available","Fever|Dengue|Chikungunya|Zika Virus","Other: biological sample collection|Other: quality of life questionnaire EuroQol®|Other: Health Assessment Questionnaire - MDHAQ and RAPID3","Occurrence, during follow-up (for 12 weeks following symptom onset), of shock, internal bleeding, failure of one or several organs or systems (brain, heart, lung, liver, kidney, clotting system), or death.|Specific complications: Onset of hemorrhagic fever (dengue) Onset of encephalitis or neurological disorders (West Nile virus, Japanese encephalitis, Zika virus) Onset of chronic form (Chikungunya)","University Hospital Center of Martinique|Institut National de la Santé Et de la Recherche Médicale, France|Clinique Antilles-Guyane","All","Child, Adult, Older Adult",,"1377","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","09/B/08","June 2010","July 2021","July 2021","April 8, 2010",,"July 24, 2019","Hôpital Bichat-Claude Bernard, Paris, France|CH André Rosemond, Cayenne, French Guiana|CHU de Pointe à Pitre/Abymes, Pointe à Pitre, Guadeloupe|Centre Hospitalier Universitaire de Martinique, Fort-de-France, Martinique",,"https://ClinicalTrials.gov/show/NCT01099852"
50,"NCT03631719","Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia","WMP-COL","Recruiting","No Results Available","Dengue|Chikungunya Virus Infection|Zika Virus Infection","Biological: Wolbachia-carrying Ae.aegypti mosquitoes","Dengue cases notified to surveillance system|Virologically-confirmed dengue|IgM test positive for dengue|Severe dengue cases|Zika cases notified to surveillance system|Chikungunya cases notified to surveillance system|Spatial analysis|Virologically-confirmed chikungunya infection|Virologically-confirmed Zika infection","Universidad de Antioquia|Monash University|United States Agency for International Development (USAID)|Bill and Melinda Gates Foundation|Wellcome Trust","All","3 Years and older   (Child, Adult, Older Adult)",,"500","Other|U.S. Fed","Observational","Observational Model: Case-Control|Time Perspective: Prospective","PEC004_18|PECET-002","October 25, 2017","December 31, 2019","December 31, 2019","August 15, 2018",,"February 25, 2019","Universidad de Antioquia, Medellín, Antioquia, Colombia",,"https://ClinicalTrials.gov/show/NCT03631719"
51,"NCT03206541","Neurologic Manifestations of the Arbovirus Infection in Colombia",,"Completed","No Results Available","Encephalitis|Myelitis|Guillain-Barre Syndrome|Cranial Nerve Palsies|Meningitis|Zika Virus Infection|Dengue (Virus); Fever, Sandfly|Chikungunya Fever",,"Neurological outcomes in arbovirus infections|Viral genotype|Immune response","Johns Hopkins University|Universidad del Valle, Colombia|ZikaPLAN","All","8 Years and older   (Child, Adult, Older Adult)",,"570","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","IRB00093149","January 1, 2016","December 31, 2019","December 31, 2019","July 2, 2017",,"February 20, 2020","Clinica Leon XIII, Medellín, Antioquia, Colombia|Neuroclinica, Medellín, Antioquia, Colombia|Clinica La Misericordia Internacional, Barranquilla, Atlantico, Colombia|Clinica Medilaser, Neiva, Huila, Colombia|Hospital Universitario de Neiva, Neiva, Huila, Colombia|Hospital Universitario de Narino, Pasto, Narino, Colombia|Hospital Universitario Erasmo Meoz, Cúcuta, Norte De Santander, Colombia|Hospital Universitario del Valle, Cali, Valle Del Cauca, Colombia",,"https://ClinicalTrials.gov/show/NCT03206541"
52,"NCT03641339","Defining Skin Immunity of a Bite of Key Insect Vectors in Humans",,"Completed","No Results Available","Zika|Dengue|Malaria|Chikungunya|Leishmaniasis","Other: Vector Feeding","To compare the early innate immune response in the skin of bitten (case) versus unbitten (control) skin for each of the three vector groups (Aedes, Anopheles, sand flies).|To characterize the local skin adaptive immune response after multiple exposures over time to bites of each of the three vector groups (Aedes, Anopheles, sand flies)|To analyze systemic immune response to vector salivary proteins in vector-naive participants in each group (Aedes, Anopheles, sand flies).|To analyze systemic immune response to vector salivary proteins in vector-experienced participants in each group (Aedes, Anopheles,sand flies).","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years to 64 Years   (Adult)","Not Applicable","95","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","180139|18-I-0139","September 5, 2018","August 13, 2019","August 13, 2019","August 22, 2018",,"August 15, 2019","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03641339"
53,"NCT02809443","Study of GLS-5700 in Healthy Volunteers",,"Completed","No Results Available","Healthy","Biological: GLS-5700","Mean change from baseline in safety laboratory measures|Incidence of solicited adverse events after vaccination|Incidence of unsolicited adverse events after vaccination|Incidence of serious adverse events|Binding antibody titers to Zika envelope|Neutralizing antibody response against Zika virus|T cell response","GeneOne Life Science, Inc.|Inovio Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Zika-001","July 2016","November 2017","December 2017","June 22, 2016",,"August 1, 2018","Miami Research Associate, Miami, Florida, United States|University of Pennslyvania, Philadelphia, Pennsylvania, United States|CHU de Québec -Université Laval hopital CHUL Centre de Recherche en infectiologie, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02809443"
54,"NCT03078894","A Pilot Study Examining for the Presence of Fecal Coliforms and Tropical Diseases in Peru",,"Unknown status","No Results Available","Tropical Disease","Diagnostic Test: Zika|Diagnostic Test: Chikagunya|Diagnostic Test: Dengue","The number of contaminated water bodies|Proportion of population with Zika, Dengue or Chikagunya infections","BioRed LLC","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CUIRBTL231","March 17, 2017","May 1, 2017","May 1, 2017","March 14, 2017",,"March 31, 2017","BioRed, Patapo, Lambayeque, Peru|BioRed, Pucala, Lambayeque, Peru|BioRed, Tuman, Lambayeque, Peru|BioRed, Pomalca, Peru",,"https://ClinicalTrials.gov/show/NCT03078894"
55,"NCT03553277","Spatial Repellents for Arbovirus Control",,"Completed","No Results Available","Arbovirus Infections","Other: transfluthrin|Other: placebo","Incidence of DCZV infections|Aedes spp. pupal density|Aedes spp. adult density|Aedes spp. female blood fed density|Aedes spp. female parous density|Perception of product efficacy","University of Notre Dame|University of California, Davis","All","2 Years and older   (Child, Adult, Older Adult)","Not Applicable","15730","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","18-01-4370","June 2015","January 2019","January 2019","June 12, 2018",,"February 18, 2019","University of California, Davis, Iquitos, Peru",,"https://ClinicalTrials.gov/show/NCT03553277"
56,"NCT03534245","Investigating Vector-Borne Determinants of Aedes Transmitted Arboviral Infections in Cambodia: An Observational Longitudinal Cohort Study in Children",,"Active, not recruiting","No Results Available","Dengue Fever",,"Prevalence of symptomatic and inapparent dengue infection (serotypes 1-4) as detected semiannually via ELISA assay (binary outcome present/absent) over a three-year period in Kampong Speu in children aged 2-9 years old|Prevalence of Aedes aegypti salivary gland homogenate reactivity as detected by ELISA assay (binary outcome present/absent) during wet and dry seasons over a three-year period in Kampong Speu in children aged 2-9 years old|Western blot analysis of sera from participants with strongest ELISA positivity to Ae. aegypti whole salivary gland homogenate compared to Anopheles and Culex to assess cross-reactive immunogenicity to mosquito saliva versus specific Aedes marke...|Positive RT-PCR result for diagnosis of dengue, chikungunya, and Zika viruses (or IgM capture ELISAs for dengue as needed)|Geographic information system with all data components (mosquito catch sites, houses, schools) referenced by latitude and longitude in addition to a series of map layers (point maps, smoothed maps) to evaluate relationships between IgG intensity...|Seroconversion to Ae. aegypti salivary homogenate in relationship to season (wet versus dry) and collected time-dependent variables defined as mean and maximum rainfall, te,perature and humidity|Capture a minimum of 25 female Aedes aegypti mosquitoes for transcriptional comparison to LMVR-reared Aedes aegypti mosquitoes","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","2 Years to 9 Years   (Child)",,"775","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","999918100|18-I-N100","May 16, 2018","September 30, 2021","September 30, 2021","May 23, 2018",,"July 17, 2019","Kampong Speu Referral Hospital, Chbar Mon, Kampong Speu, Cambodia",,"https://ClinicalTrials.gov/show/NCT03534245"
57,"NCT02957344","Parental Views Related to Colorado State Legislation About Vaccinations, Schools, and Child Care Centers",,"Completed","No Results Available","Healthy Children",,"Survey/Questionnaire of parental knowledge and attitudes related to vaccines, schools, and child care centers.","University of Colorado, Denver","Female","18 Years and older   (Adult, Older Adult)",,"679","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","11-1149a","August 2016","November 2016","November 2016","November 6, 2016",,"January 19, 2017","University of Colorado Denver, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT02957344"
